SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-22-038149
Filing Date
2022-10-24
Accepted
2022-10-24 06:12:02
Documents
7

Document Format Files

Seq Description Document Type Size
1 DEFA14A ny20005635x2_defa14a.htm DEFA14A 42870
2 EXHIBIT 2.1 ny20005635x2_ex2-1.htm EX-2.1 628460
3 EXHIBIT 10.1 ny20005635x2_ex10-1.htm EX-10.1 60099
4 EXHIBIT 99.1 ny20005635x2_ex99-1.htm EX-99.1 24020
5 EXHIBIT 99.2 ny20005635x2_ex99-2.htm EX-99.2 14107
6 EXHIBIT 99.3 ny20005635x2_ex99-3.htm EX-99.3 11443
7 ny20005635x2_ex2-1img01.jpg GRAPHIC 2478
  Complete submission text file 0001140361-22-038149.txt   785573
Mailing Address SUITE 1, 3RD FLOOR 11-12 ST. JAMES SQUARE LONDON X0 SW1Y 4LB
Business Address SUITE 1, 3RD FLOOR 11-12 ST. JAMES SQUARE LONDON X0 SW1Y 4LB 44 207-400-3351
Myovant Sciences Ltd. (Filer) CIK: 0001679082 (see all company filings)

IRS No.: 000000000 | State of Incorp.: CA | Fiscal Year End: 0331
Type: DEFA14A | Act: 34 | File No.: 001-37929 | Film No.: 221324781
SIC: 2834 Pharmaceutical Preparations